This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/drug/DB08834/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08834/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB08834/identifier/kegg-compound/
n11http://www.drugs.com/international/

Statements

Subject Item
n2:DB08834
rdf:type
n4:Drug
n4:description
Tauroursodeoxycholic acid is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans. Tauroursodeoxycholic acid, on the other hand, is produced abundantly in bears and has been used for centuries as a natural remedy in some Asian countries. It is approved in Italy and Turkey for the treatment of cholesterol gallstones and is an investigational drug in China, Unites States, and Italy. Tauroursodeoxycholic acid is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis. The only completed clinical trial thus far is a phase III clinical trial comparing tauroursodeoxycholic acid and ursofalk in PBC adult patients, but as of June 2013 no results of this trial have been published.
n4:generalReferences
# Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9486191 # Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G: Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012 Jun;19 Suppl 1:34-6. doi: 10.3109/13506129.2012.678508. Epub 2012 May 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22551192
n4:group
approved investigational
n4:indication
Used in the treatment of cholesterol gallstones. Tauroursodeoxycholic acid is also being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
owl:sameAs
n7:DB08834
dcterms:title
Tauroursodeoxycholic acid
adms:identifier
n9:Tauroursodeoxycholic_acid n12:DB08834 n13:C16868
n4:mechanismOfAction
Tauroursodeoxycholic acid is the more hydrophilic form of ursodeoxycholic acid, which is naturally produced in the body. In patients with properly functioning gallbladders, both of these bile acids inhibit liver cholesterol secretion and synthesis as well as intestinal cholesterol absorption allowing for the promotion of cholesterol gallstone dissolution. The mechanism of action of tauroursodeoxycholic acid in the other conditions is still being investigated.
n4:synonym
TUDCA Tauroursodeoxycholate
n4:synthesisReference
Zhuo, Chao; Feng, Wei; Wu, Da-jun; Xiong, Zhi-gang. Synthesis of tauroursodeoxycholic acid. Hecheng Huaxue (2002), 10(5), 444-446.
foaf:page
n11:tauroursodeoxycholic-acid.html
n4:IUPAC-Name
n5:271B57E6-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B57EC-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B57EB-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B57E8-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B57E9-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B57EA-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B57E4-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B57E5-363D-11E5-9242-09173F13E4C5 n5:271B57E2-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B57E3-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Acceptor-Count
n5:271B57F2-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B57F3-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B57ED-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B57EE-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B57F0-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B57EF-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B57F1-363D-11E5-9242-09173F13E4C5
n4:affectedOrganism
Humans and other mammals
n4:casRegistryNumber
14605-22-2
n4:category
n4:Bioavailability
n5:271B57F8-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B57FA-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B57FB-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B57F7-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B57F6-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B57F9-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B57E7-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-acidic-
n5:271B57F4-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B57F5-363D-11E5-9242-09173F13E4C5